Tamra Sami

1 week ago | bioworld.com | Tamra Sami

Telix’s brain cancer radiotherapy shows phase II survival benefitTelix Pharmaceuticals Ltd.’s glioblastoma theranostic, TLX-101, is showing promising overall survival in a phase II trial in recurrent high-grade glioma. The targeted radiation therapy, combined with external beam radiation therapy, demonstrated a median overall survival of 12.4 months from treatment initiation and 32.2 months from initial diagnosis.

1 week ago | bioworld.com | Tamra Sami

China’s NMPA accepts Innocare’s zurletrectinib NDA for solid tumorsChina’s National Medical Products Administration (NMPA) has accepted Innocare Pharma Ltd.’s NDA for its second-generation pan-tropomyosin receptor kinase inhibitor, zurletrectinib (ICP-723), for treating adults and adolescents with advanced solid tumors harboring neurotrophic tyrosine receptor kinase gene fusions. BioWorld Regulatory Cancer Asia-Pacific China NDA NMPA

1 week ago | bioworld.com | Tamra Sami

Home » Tryptamine to test injectable psilocybin for binge eating disorder BioWorld briefs for April 14, 2025. BioWorld MedTech briefs for April 14, 2025. At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald... Researchers have developed a new compound that can prevent long COVID symptoms in mice that could lead to a future drug for the debilitating condition in humans....

1 week ago | bioworld.com | Tamra Sami

US-China trade war accelerates with biotech in the crosshairs The U.S. National Security Commission on Emerging Biotechnology (NSCEB) is urging Congress to reinvest in American biotechnology because “the U.S. is dangerously close to falling behind China,” according to a May 8 report. "The United States is locked in a competition with China that will define the coming century," said NSCEB Chair Senator Todd Young (R-Ind.). “Biotechnology is the next phase in that competition.

1 week ago | bioworld.com | Tamra Sami

Hightide’s HTD-1801 meets phase III endpoints in type 2 diabetesHightide Therapeutics Inc.’s berberine ursodeoxycholate (HTD-1801) met primary and secondary endpoints in the Symphony 1 and Symphony 2 phase III trials in type 2 diabetes in Chinese patients. Based on the data, Shenzhen-based Hightide will submit an NDA to China’s National Medical Products Administration (NMPA) later this year. BioWorld BioWorld Asia Clinical Diabetes Endocrine/metabolic Gastrointestinal Asia-Pacific China NMPA